Screening Libraries

Compound Collections

The choice of which chemical libraries to screen should be guided by the goals of the project and the biological system of interest.

Biochemical screens seeking novel chemical entities capable of binding to a protein and modulating its function would be best served by diverse collections of drug-like small molecules such as the Maybridge HitFinder or the Chembridge MicroFormats. Confirmation and optimization of hits and can be managed by enlisting advice, collaborations, or through further contract work with the HTSC.

Cellular assays can reveal insights into the biological regulation of your phenotype with “known actives” and “approved drugs” collections. Screening characterized collections serves as a set of baseline controls to help hone the assay system and avoid false positives resulting from undesired biological effects. For example, one may wish to develop counter-screens to weed out cytotoxic compounds from consideration in a neuroscience screen. Many of the compounds in these collections have been validated in animals, allowing a progression to disease models by removing the hurdle of toxicology, pharmacokinetic, and pharmacodynamic studies.

If investigators would like to develop novel chemical compounds as hits with a long term view toward drug discovery, it is advisable to screen large and diverse collections of drug-like small molecules.

Compound Libraries

Library Size Compound Type
Bioactive Lipids 190 Known
Chembridge 100,000 Diverse
Maybridge 14,400 Diverse
NCI Diversity II 2,000 Diverse
Spectrum 2,000 Known/Diverse
Pharmakon 1,600 Known Drugs
ICCB Bioactives 480 Known

 

siRNA Libraries

Library Size (# genes) Redundancy
Human Kinases 646 2 oligos per gene
Human Phosphatases 222 2 oligos per gene
Human Druggable Genome 6,992 4 oligos per gene
Human Genome 21,687 3 oligos per gene

logo for htsc footer no background